A TDF lawsuit is a type of personal injury case that seeks compensation for people who were injured by a TDF drug. Injuries caused by TDF drugs can range from muscle weakness to bone fracture. The Showard Law Firm is experienced in filing TDF lawsuits for individuals who have experienced adverse effects after taking these drugs. As the litigation continues, free consultations will be available. Here are a few things you should know before filing a TDF lawsuit.
The TDF drug was known to cause severe bone and kidney injury. Because Gilead knew of these risks, it lacked the means to warn doctors and patients about them. Furthermore, Gilead delayed the introduction of a less toxic alternative, resulting in prolonged exposure to TDF drugs. The less toxic alternative to TDF is called TAF. Because TDF is not as effective, this lawsuit is filed in an effort to recover compensation for the victims.
The first TDF lawsuit was filed in California state court in May 2016. Since then, two more TDF lawsuits were filed in 2018. The San Francisco Superior Court has consolidated TDF litigation to make the process faster and more efficient. A Bellwether trial for 14 test cases has been scheduled for April 2022. Further bellwether trials are hoped to provide a starting point for settling TDF lawsuits. This is particularly important because the number of TDF lawsuit is growing and the complexity of the litigation will require years to compile enough evidence to prove the company is responsible.
The Gilead patents on TDF were not allowed to expire until 2010, when Gilead developed an alternative. Gilead also allegedly waited until the patents on TAF expired before releasing it to the public. This resulted in a growing number of lawsuits against the company, and a new, safer drug was finally approved by the FDA in November 2015.
There are more than 4,000 cases of TDF injuries worldwide. The largest TDF lawsuit was filed in May 2018 by the AIDS Health Foundation. This case highlights the dangers associated with TDF and how the drug failed to warn people of serious side effects. The FDA also reprimanded the manufacturer of TDF in 2002, but the company continued to mislead doctors about the drug's risks. This is a pending class action lawsuit in California state court.
In 2001, the FDA issued warning letters to Gilead regarding the marketing of TDF. The letter referred to a Gilead sales representative who allegedly made misleading statements about the drug's safety. The FDA found that Gilead was promoting Viread as a safer alternative to other HIV drugs. Those statements ultimately led to increased prescriptions and sales for the drug. In fact, domestic sales of Viread reached $59.4 million in 2003.
While TDF-based drugs are a lifesaving option for people living with HIV, they are causing serious side effects. Gilead knew about the risks associated with TDF-based drugs, but withheld the more effective alternative in order to maximize their profits. This must stop and make Gilead accountable. So far, there have been only nine lawsuits filed against TDF, with the most important being in New York and California.
No comments:
Post a Comment